We’ve recently updated our valuation analysis.

Amarin Valuation

Is AMRN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AMRN?

Other financial metrics that can be useful for relative valuation.

AMRN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.4x
Enterprise Value/EBITDA-3.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does AMRN's PS Ratio compare to its peers?

The above table shows the PS ratio for AMRN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average16.9x
INO Inovio Pharmaceuticals
43.2x79.4%US$474.0m
VECT VectivBio Holding
20x64.1%US$517.5m
EGRX Eagle Pharmaceuticals
1.6x-1.9%US$467.1m
ANIK Anika Therapeutics
2.8x11.0%US$443.3m
AMRN Amarin
1.1x9.3%US$472.5m

Price-To-Sales vs Peers: AMRN is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (16.9x).


Price to Earnings Ratio vs Industry

How does AMRN's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.4%
n/an/an/a

Price-To-Sales vs Industry: AMRN is good value based on its Price-To-Sales Ratio (1.1x) compared to the US Biotechs industry average (11.8x)


Price to Sales Ratio vs Fair Ratio

What is AMRN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AMRN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.1x
Fair PS Ratio3.5x

Price-To-Sales vs Fair Ratio: AMRN is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).


Share Price vs Fair Value

What is the Fair Price of AMRN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AMRN ($1.12) is trading below our estimate of fair value ($7.66)

Significantly Below Fair Value: AMRN is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AMRN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.12
US$3.33
+197.2%
78.4%US$9.00US$1.30n/a7
Nov ’23US$1.29
US$3.33
+158.0%
78.4%US$9.00US$1.30n/a7
Oct ’23US$1.09
US$3.57
+227.7%
69.6%US$9.00US$1.50n/a7
Sep ’23US$1.17
US$3.57
+205.3%
69.6%US$9.00US$1.50n/a7
Aug ’23US$1.29
US$3.57
+176.9%
69.6%US$9.00US$1.50n/a7
Jul ’23US$1.44
US$3.57
+148.0%
69.6%US$9.00US$1.50n/a7
Jun ’23US$1.45
US$3.57
+146.3%
69.6%US$9.00US$1.50n/a7
May ’23US$2.69
US$7.93
+194.7%
37.6%US$10.00US$3.00n/a7
Apr ’23US$3.53
US$7.93
+124.6%
37.6%US$10.00US$3.00n/a7
Mar ’23US$3.19
US$8.83
+176.9%
51.5%US$19.00US$3.00n/a9
Feb ’23US$3.73
US$9.17
+145.8%
47.7%US$19.00US$3.00n/a9
Jan ’23US$3.37
US$9.39
+178.6%
45.6%US$19.00US$4.00n/a9
Dec ’22US$3.71
US$9.50
+156.1%
43.7%US$19.00US$4.50n/a9
Nov ’22US$4.83
US$10.33
+113.9%
41.8%US$19.00US$5.00US$1.299
Oct ’22US$5.11
US$10.33
+102.2%
41.8%US$19.00US$5.00US$1.099
Sep ’22US$5.43
US$10.13
+86.5%
44.8%US$19.00US$5.00US$1.178
Aug ’22US$4.14
US$9.78
+136.2%
44.7%US$19.00US$5.00US$1.299
Jul ’22US$4.46
US$9.78
+119.2%
44.7%US$19.00US$5.00US$1.449
Jun ’22US$4.60
US$9.78
+112.6%
44.7%US$19.00US$5.00US$1.459
May ’22US$5.09
US$9.89
+94.3%
43.0%US$19.00US$6.00US$2.699
Apr ’22US$6.48
US$10.10
+55.9%
39.2%US$19.00US$6.00US$3.5310
Mar ’22US$6.19
US$10.33
+66.9%
39.6%US$19.00US$6.00US$3.1912
Feb ’22US$8.08
US$10.08
+24.8%
43.1%US$19.00US$5.00US$3.7312
Jan ’22US$4.89
US$10.00
+104.5%
41.1%US$19.00US$5.00US$3.3711
Dec ’21US$4.91
US$11.09
+125.9%
36.6%US$19.00US$5.00US$3.7111
Nov ’21US$4.86
US$11.40
+134.6%
40.6%US$21.00US$5.00US$4.8310

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies